Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merrimack Pharmaceuticals
• Collaborator: Sanofi
• Treatments: Antibodies, Monoclonal; Carboplatin; Gemcitabine; Pemetrexed

Criteria

Inclusion Criteria:

• Advanced-stage solid tumors

• ≥ 18 years of age

• Adequate liver and kidney function

Exclusion Criteria:

• Any other active malignancy

• No known HIV, Hepatitis C or B